Defiance Launches Europe’s First Memory UCITS ETF (DRAM)

  • Defiance has expanded its European ETF lineup with the launch of the Defiance Memory UCITS ETF (ticker: DRAM).
  • The ETF seeks to provide exposure to companies involved in the development, manufacturing, commercialisation, and storage of memory semiconductors and data storage systems.
  • In the U.S., memory-focused ETFs have gathered around $20 billion in assets under management (AUM).1
  • The ETF is listed on Xetra and Borsa Italiana, with the London Stock Exchange to follow.

MIAMI, June 19, 2026 (GLOBE NEWSWIRE) — Defiance ETFs is excited to announce the launch of the Defiance Memory UCITS ETF (ticker: DRAM), Europe’s first memory ETF. The Fund seeks to provide exposure to companies involved in the development, manufacturing, commercialisation, and storage of memory semiconductors and data storage systems.

Defiance Memory UCITS ETF

ISIN: IE000CEUZ052
TER: 0.69%

Exchange Bloomberg Ticker SEDOL Trading Currency
Xetra DRAM GY BVVG296 EUR
Borsa Italiana DRAM IM BVVG2B8 USD


Memory prices are moving higher. Demand from AI, cloud computing, and data centres is absorbing a growing share of advanced memory capacity, while major manufacturers are prioritising higher-margin areas such as high-bandwidth memory and server-grade DRAM (Dynamic Random Access Memory) over more commoditised consumer applications.2

This shift is creating pressure across the wider technology supply chain. As supply is redirected towards AI infrastructure and hyperscale data centres, manufacturers of everyday devices are facing higher input costs and tighter availability.

This year, it is expected that there will not be enough memory to meet worldwide demand.3 DRAM and solid-state drive (SSD) prices could rise as much as 130% by the end of 2026, according to Gartner.4

Exposure to the memory sector through ETFs has so far only been possible in the U.S., where assets are now around $20 billion.5 The Defiance Memory UCITS ETF seeks to give European investors the opportunity to access the memory sector, which will need to expand to keep up with AI-driven demand.

This is Defiance’s 4th launch since entering the European UCITS ETF market earlier this year.

Defiance UCITS Lineup Ticker
Defiance AI & Power Infrastructure UCITS ETF AIPO
Defiance Memory UCITS ETF DRAM
Drone UCITS ETF DRON
Ukraine Reconstruction UCITS ETF UKRN



Sylvia Jablonski, CIO of Defiance ETFs, commented:
“Memory is the foundational layer of the AI economy. Every model training run, inference workload, and hyperscale data centre expansion depends on DRAM, HBM, and advanced storage. DRAM gives European investors a direct, rules-based way to access this segment of the AI value chain, complementing the power infrastructure exposure already available through AIPO.”

Hector McNeil, Co-Founder and Co-CEO of HANetf, commented: “We are delighted to be partnering with Defiance to launch the Defiance Memory UCITS ETF. The ETF captures a sector that has seen significant growth recently, driven predominantly by the rise of AI and its infrastructure. This ETF particularly complements Defiance’s AIPO ETF, which provides access to the power infrastructure behind the AI buildout.”

For full fund details, including the prospectus and Key Information Document, visit hanetf.com.

About Defiance ETFs

Founded in 2018, Defiance is a leading ETF issuer specializing in thematic, income, and leveraged ETFs. The firm manages 75+ ETFs designed to provide targeted exposure to high-growth sectors including AI infrastructure, quantum computing, drones and modern warfare, and other emerging technologies.

About HANetf

HANetf is an independent provider of UCITS ETFs, working with asset management companies to bring differentiated, modern, and innovative exposures to European ETF investors. Via our white-label ETF platform, HANetf provides a complete operational, regulatory, distribution and marketing solution for asset managers to launch and manage UCITS ETFs. www.hanetf.com

Media Contact

Brenda Hentschel | [email protected] | 201.705.3758

For European media enquiries:

Italy: Elena Soffientini, Mymediarelation | [email protected] | +39 375 670 62 07
Germany: Caroline Chojnowski, Public Imaging | [email protected] | +49 (0)40-401 999 – 23

Important Information

Communications issued in the European Economic Area (“EEA”)

The content in this document is issued and approved by HANetf EU Limited (“HANetf EU”). HANetf EU is authorised and regulated by the Central Bank of Ireland. HANetf EU is registered in Ireland with registration number 728832.

Communications issued in the UK

The content in this document is issued by HANetf Limited (“HANetf”) and approved by Privium Fund Management (UK) Limited (“Privium”). HANetf is an appointed representative of Privium, which is authorised and regulated by the Financial Conduct Authority. The registered office of Privium is The Shard, 24th Floor, 32 London Bridge Street, London, SE1 9SG.

This communication has been prepared for professional investors, but the ETCs and ETFs set out in this communication (“Products”) may be available in some jurisdictions to any investors. Please check with your broker or intermediary that the relevant Product is available in your jurisdiction and suitable for your investment profile.

Past performance is not a reliable indicator of future performance. The price of the Products may vary and they do not offer a fixed income.

This document may contain forward looking statements including statements regarding our belief or current expectations with regards to the performance of certain assets classes. Forward looking statements are subject to certain risks, uncertainties and assumptions. There can be no assurance that such statements will be accurate and actual results could differ materially from those anticipated in such statements. Therefore, readers are cautioned not to place undue reliance on these forward-looking statements.

The content of this document is for information purposes and for your internal use only, and does not constitute an investment advice, recommendation, investment research or an offer for sale nor a solicitation of an offer to buy any Product or make any investment.

An investment in an exchange traded product is dependent on the performance of the underlying asset class, less costs, but it is not expected to track that performance exactly. The Products involve numerous risks including among others, general market risks relating to underlying adverse price movements in an Index (for ETFs) or underlying asset class and currency, liquidity, operational, legal and regulatory risks. In addition, in relation to Cryptocurrency ETCs, these are highly volatile digital assets and performance is unpredictable.

The information contained on this document is not, and under no circumstances is to be construed as, an advertisement or any other step in furtherance of a public offering of securities in the United States or any province or territory thereof, where none of the Issuers (as defined below) or their Products are authorised or registered for distribution and where no prospectus of any of the Issuers has been filed with any securities commission or regulatory authority. No document or information on this document should be taken, transmitted or distributed (directly or indirectly) into the United States. None of the Issuers, nor any securities issued by it, have been or will be registered under the United States Securities Act of 1933 or the Investment Company Act of 1940 or qualified under any applicable state securities statutes.

The Issuers:
1. HANetf ICAV and HANetf ICAV II are open-ended Irish collective asset management vehicles and are the issuers of the ETFs under the terms in the relevant Prospectuses and relevant Supplements for each ETF approved by the Central Bank of Ireland (“CBI”) (each an “ETF Prospectus” and together the “ETF Prospectuses”). Investors should read the current version of the relevant ETF Prospectus before investing and should refer to the section of the relevant ETF Prospectus entitled ‘Risk Factors’ for further details of risks associated with an investment in the ETFs. Any decision to invest should be based on the information contained in the ETF Prospectuses.

2. HANetf ETC Securities plc, a public limited company incorporated in Ireland, issuing under the terms in the Base Prospectus approved by the Central Bank of Ireland and the final terms of the relevant series (“ETC Securities Documentation”) is the issuer of the precious metals ETCs. Investors should read the latest version of the ETC Securities Documentation before investing and should refer to the section of the Base Prospectus entitled ‘Risk Factors’ for further details of risks associated with an investment in the ETCs. Any decision to invest should be based on the information contained in the ETC Securities Documentation.

3. Bitwise Europe GmbH, a limited liability company incorporated under the laws of the Federal Republic of Germany, issuing under the terms in the Prospectus approved by the Bundesanstalt für Finanzdienstleistungsaufsicht (“BaFin”) and the final terms (“Cryptocurrency Prospectus”) is the issuer of the ETCM ETCs. Investors should read the latest version of the Cryptocurrency Prospectus before investing and should refer to the section of the Cryptocurrency Prospectus entitled ‘Risk Factors’ for further details of risks associated with an investment in the ETCs contained in the Cryptocurrency Prospectus. Any decision to invest should be based on the information contained in the Cryptocurrency Prospectus.

4. HANetf Multi-Asset ETC Issuer plc, a public company incorporated in Jersey, issuing under the terms in the Base Prospectuses approved by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) (the “SFSA”), the United Kingdom Financial Conduct Authority (“FCA”) and the final terms of the relevant series (“Multi-Asset ETC Securities Documentation”) is the issuer of ETCs linked to and secured by various underlying assets. Investors should read the latest version of the ETC Securities Documentation before investing and should refer to the section of the relevant Base Prospectus entitled ‘Risk Factors’ for further details of risks associated with an investment in the ETCs. Any decision to invest should be based on the information contained in the ETC Securities Documentation.

The relevant ETF Prospectuses, ETC Securities Documentation, Multi-Asset ETC Securities Documentation and Cryptocurrency Prospectus can all be downloaded from www.hanetf.com.

The decision and amount to invest in any Product should take into consideration your specific circumstances after seeking independent investment, tax and legal advice. We do not control and are not responsible for the content of third-party websites.

We believe the information in this document is based on reliable sources, but its accuracy cannot be guaranteed. The views expressed are the views of HANetf at time of publication and may change. Neither Privium nor HANetf is liable for any losses relating to the accuracy, completeness or use of information in this communication, including any consequential loss.

FOR SWISS INVESTORS ONLY: The Fund has appointed as Swiss Representative Waystone Fund Services (Switzerland) SA, Av. Villamont 17, 1005 Lausanne, Switzerland, Tel: +41 21 311 17 77, email: [email protected]. The Fund’s Swiss paying agent is Helvetische Bank AG. The Prospectus, the Key Investor Information Documents, the Instrument of Incorporation as well as the annual and semi-annual reports may be obtained free of charge from the Swiss Representative in Lausanne. The issue and redemption prices are published at each issue and redemption on www.fundinfo.com.


1
Source: ETFBook. Data as at 06/16/2026.
2Source: Forbes, 2026.
3Source: CNBC, 2026.
4Source: Gartner, 2026.
5Source: ETFBook. Data as at 06/16/2026.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a566fcca-b8ad-4109-9d41-2af9ee73c275



Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

WILMINGTON, Del.–(BUSINESS WIRE)–
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

“This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.”

DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1

The approval is based on results from the MOR208C203 Trial: L-MIND (NCT02399085), an international Phase II trial, and INCMOR 0208-102 Trial Part 4 (Group 6): J-MIND (NCT04661007), a domestic Phase Ib/II trial in Japan, both of which evaluated the safety and efficacy of Minjuvi in combination with lenalidomide in patients with relapsed or refractory DLBCL who are not eligible for autologous stem cell transplant (ASCT).2,4 In the L-MIND trial, based on an independent review committee assessment (data cutoff date: November 20, 2018), the overall response rate (ORR) was 58.8% (primary endpoint), with a complete response (CR) rate of 41.3% and a partial response (PR) rate of 17.5%.3 The median duration of response (mDOR) had not been reached at a median follow-up of 44 months or more.3 Furthermore, based on the independent review committee’s assessment in the J-MIND trial (data cutoff date: August 31, 2023), the response rate was 71.4%, with a complete response (CR) rate of 45.2% and a partial response (PR) rate of 26.2%.4 The main adverse events included neutropenia and thrombocytopenia.4,5 Overall, Minjuvi in combination with lenalidomide demonstrated a clinically meaningful response, and the side effects were manageable.4,5

This approval represents the second regulatory approval for Minjuvi in Japan. Minjuvi in combination with rituximab and lenalidomide was previously approved by the MHLW for the treatment of adult patients with relapsed or refractory follicular lymphoma (2L+ FL).

About L-MIND

L-MIND was a single-arm, open-label Phase 2 study evaluating tafasitamab in combination with lenalidomide in adults with relapsed or refractory diffuse large B-cell lymphoma who had received at least one, but no more than three, prior lines of therapy (including an anti-CD20 therapy such as rituximab) and who were not eligible for, or refused, high-dose chemotherapy followed by autologous stem cell transplant.2 The primary endpoint was overall response rate; secondary endpoints included duration of response, progression-free survival, and overall survival.2

For more information about the study, please visit https://clinicaltrials.gov/study/NCT02399085.

About J-MIND

J-MIND Trial Part 4 (Group 6) (NCT04661007) is a Japanese Phase Ib/II clinical trial evaluating the efficacy and safety of tafasitamab in combination with lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Patients enrolled in this trial had received one to three prior systemic therapies, including CD20-targeted therapy, and were deemed by the principal investigator to be ineligible for or unresponsive to autologous hematopoietic stem cell transplantation.4

The primary endpoint of this trial was the objective response rate (ORR) as assessed by an independent review committee based on the Lugano criteria; secondary endpoints included complete response (CR), progression-free survival (PFS), and overall survival (OS).4

For more information about the study, please visit https://clinicaltrials.gov/study/NCT04661007.

About Minjuvi® (tafasitamab)

Minjuvi® (tafasitamab) is a humanized, Fc-modified, cytolytic CD19-targeting monoclonal antibody. Tafasitamab incorporates an XmAb® engineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanisms, including antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). Incyte licenses exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc.

In the U.S., Monjuvi® (tafasitamab-cxix) received accelerated approval in the United States in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low-grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).6 Additionally, Monjuvi is approved by the U.S. FDA in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL).6

In Europe, Minjuvi (tafasitamab) received conditional marketing authorization from the European Medicines Agency in combination with lenalidomide, followed by Minjuvi monotherapy, for the treatment of adult patients with relapsed or refractory DLBCL who are not eligible for ASCT.7 Additionally, Minjuvi is approved in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) (Grade 1–3a) after at least one line of systemic therapy in Europe.7

In Japan, Minjuvi is approved in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in Japan.8 Minjuvi is also approved in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL).

XmAb® is a registered trademark of Xencor, Inc.

Monjuvi and Minjuvi are registered trademarks of Incyte.

Important Safety Information

Please refer to the Minjuvi Product Information (PI) for indications, dosage and administration, precautions, and safety information in Japan, as well as the Pharmaceuticals and Medical Devices Agency (PMDA) website.

About Incyte®

Incyte is redefining what’s possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive portfolio of next-generation medicines across our key franchises: Hematology, Oncology and Inflammation & Autoimmunity.

To learn more, visit Incyte.com and Investor.Incyte.com. Follow us on social media: LinkedIn, X and Instagram.

Incyte Biosciences Japan G.K. is a wholly owned subsidiary of Incyte. For more information about Incyte in Japan, visit www.incyte.jp.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the potential for Minjuvi to provide a new treatment option for patients in Japan with DLBCL, and Incyte’s aspirations and goals as set forth under the heading “About Incyte.”

Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including Incyte’s ability to demonstrate the efficacy and safety of its products and product candidates; the sufficiency of clinical trial data to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approval; Incyte’s ability to achieve commercial success for its marketed products and product candidates, if approved; Incyte’s ability to obtain and maintain protection of intellectual property for its products and technology; Incyte’s reliance on third parties and partners; the acceptance of Incyte’s products in the marketplace; market competition; and sales, marketing, manufacturing, and distribution requirements, as well as the risks and uncertainties discussed in greater detail in Incyte’s reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2025 and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026. Incyte disclaims any intent or obligation to update these forward-looking statements.

_________________________

1 Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021;384:842–858. Link to source (https://www.nejm.org/doi/full/10.1056/NEJMra2027612)

2 ClinicalTrials.gov. Open label study to evaluate the safety and efficacy of lenalidomide with MOR00208 in patients with R-R DLBCL (L-MIND). Link to source (https://clinicaltrials.gov/study/NCT02399085). Accessed June 2026.

3 Duell J, Abrisqueta P, Andre M, Gaidano G, Gonzales-Barca E, Jurczak W, Kalakonda N, Liberati AM, Maddocks KJ, Menne T, Nagy Z, Tournilhac O, Kuffer C, Bakuli A, Amin A, Gurbanov K, Salles G. Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study. Haematologica. 2024;109(2):553–566. Link to source (https://doi.org/10.3324/haematol.2023.283480)

4 Izutsu K, Fukuhara N, Yuda J, Suehiro Y, Kusumoto S, Casadebaig ML, Suzukawa K, Fukushima K. Tafasitamab as Monotherapy or in Combination in Japanese Patients With B-Cell Non-Hodgkin Lymphoma: Results From the Phase 1b J-MIND Study. Cancer Sci. 2026 Apr;117(4):1093–1105. Link to source (https://pubmed.ncbi.nlm.nih.gov/41563911/)

5 Salles G, Duell J, González-Barca E, et al. Tafasitamab plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, Phase 2 study. Lancet Oncol. 2020;21:978–988. Link to source (https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30225-4/abstract)

6 U.S. Food and Drug Administration. Monjuvi® (tafasitamab-cxix) Prescribing Information. Accessed June 2026. Link to source (https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761163s013lbl.pdf).

7 European Medicines Agency (EMA). Minjuvi (tafasitamab) European Public Assessment Report (EPAR) and Product Information. Accessed June 2026. Link to source (https://www.ema.europa.eu/en/documents/product-information/minjuvi-epar-product-information_en.pdf).

8 Incyte. Minjuvi® (tafasitamab) Product Information (Japan) and Pharmaceuticals and Medical Devices Agency (PMDA) electronic package insert. Accessed June 2026. Link to source (https://www.info.pmda.go.jp/psearch/html/menu_tenpu_base.html).

Incyte Contacts:

Media

[email protected]

Investors

[email protected]

KEYWORDS: North America United States Asia Pacific Europe Japan Delaware

INDUSTRY KEYWORDS: Biotechnology FDA Health Pharmaceutical Oncology

MEDIA:

Logo
Logo

Bielik.io Partners with BitGo Europe GmbH to Support Regulated Crypto Trading Across the EEA

Bielik.io Partners with BitGo Europe GmbH to Support Regulated Crypto Trading Across the EEA

FRANKFURT, Germany–(BUSINESS WIRE)–
BitGo Europe GmbH (“BitGo Europe”), a subsidiary of BitGo Holdings, Inc. (NYSE: BTGO) (“BitGo”), the digital asset infrastructure company, today announced a partnership with Bielik Vault Sp. z o.o. (”Bielik.io”), a Warsaw-based crypto trading platform, to support Bielik.io’s transition from Poland’s legacy Virtual Asset Service Provider framework by integrating BitGo Europe’s Crypto-as-a-Service infrastructure.

Through the integration, Bielik.io will provide eligible end users with access to digital asset services through its mobile application, including deposits, trading of supported digital assets, and custody through BitGo Europe’s infrastructure.

The partnership comes as Europe’s digital asset market continues to transition under the Markets in Crypto-Assets Regulation, or MiCAR, which establishes a unified regulatory framework for crypto-asset service providers across the European Union. In Poland, existing virtual asset service providers have been operating under a transitional regime as the country continues to implement its national MiCAR framework. By integrating BitGo Europe’s regulated infrastructure, Bielik.io is advancing its regulatory strategy while continuing to deliver a streamlined user experience.

“We believe MiCAR is creating a clearer and more consistent regulatory framework for digital assets across Europe,” said Mike Belshe, CEO and Co-founder of BitGo. “Bielik.io is taking an important step by building on regulated infrastructure designed to support secure and compliant access to digital asset services. BitGo Europe is proud to provide the custody, trading, and platform infrastructure that helps companies like Bielik.io scale responsibly across the region.”

BitGo Europe’s Crypto-as-a-Service solution provides custody, wallet, onboarding, trading, and settlement infrastructure that enables partners such as Bielik.io to offer to build, launch, and scale digital asset services within their own products. Eligible Bielik.io users can fund accounts via multiple payment methods, buy and sell more than 40 supported digital assets at present, including certain stablecoins where available, and hold assets through BitGo Europe’s institutional-grade infrastructure.

“When evaluating infrastructure partners, we had a clear set of priorities: the security of our users’ assets and their confidence in our platform had to come first. BitGo Europe GmbH allows us to uphold these standards as Europe moves toward full MiCAR implementation, making it the right long-term choice for Bielik.io,” said Konrad Lemańczyk, CEO and Founder of Bielik.io.

“For us, this marks the beginning of a long-term partnership. With BitGo Europe providing secure custody and core crypto infrastructure, we can focus on our strategic mission: developing Bielik.io into Poland’s most trusted and secure platform for accessing digital assets,” added Magdalena Rokosz, Managing Partner and Founder of Bielik.io.

The partnership reflects a broader shift across European digital asset markets as companies adapt to MiCAR and invest in regulated infrastructure designed to support the next phase of crypto adoption.

About BitGo

BitGo (NYSE: BTGO) is the digital asset infrastructure company delivering custody, wallets, staking, trading, financing, stablecoins, and settlement services from regulated cold storage. Since 2013, BitGo has focused on accelerating the transition of the financial system to a digital asset economy. BitGo maintains a global presence and multiple regulated entities, including BitGo Bank & Trust, National Association, the first federally chartered digital asset trust bank owned by a publicly traded company. Today, BitGo serves thousands of institutions, including many of the industry’s top brands, financial institutions, exchanges, and platforms, and millions of investors worldwide. For more information, visit www.bitgo.com.

Risk Warning

Crypto-assets are highly volatile and subject to rapid price fluctuations. You could lose all the money you invest. Crypto-asset services are not covered by traditional consumer protection frameworks or financial deposit guarantee schemes.

About Bielik

Bielik.io is a Polish company (Bielik Vault Sp. z o.o.), established in 2022 as a virtual asset service provider and registered with the Polish Financial Supervision Authority (KNF) as payment institution. Bielik.io’s mission is to build trust in the digital asset ecosystem by combining traditional financial services with crypto innovation. Its founders brought extensive international experience across the banking, fintech, and blockchain sectors and leveraged this expertise to create a solution that addresses the real needs of Polish users: security, simplicity, and transparency. For more information, visit www.bielik.io.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the highly volatile nature of digital assets, technical issues in connection with the integration of supported digital assets and changes and upgrades to their underlying network, heightened scrutiny of our industry and operations, the theft, loss, or destruction of private keys required to access any digital assets held in custody for our own account or for our clients, errors in executing client transactions or managing our own trading activities, and the other factors discussed in the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 27, 2026, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

Media Contact

[email protected]

KEYWORDS: Europe Germany Poland

INDUSTRY KEYWORDS: Apps/Applications Mobile/Wireless Technology Payments Finance Fintech Professional Services Digital Cash Management/Digital Assets Blockchain Cryptocurrency

MEDIA:

Logo
Logo

THE MARKET HAS SPOKEN: Wants Neugebauer and Fermi Board to Maximize Shareholder Value and Enhance Management

PR Newswire

While Surprised John Sellers and Double Eagle Declined to Take the Helm of Fermi, Neugebauer Reiterates His Call for Board to Find Someone of that Caliber with a Team Who Can Replace the Nine Senior Leaders That Departed Fermi After Toby’s Termination

Calls on the Fermi Board to Put Their Guns Down

Neugebauer Responds to Perry’s and Others’ Negative Campaign Attacks: Answers Recent Media Inquiries and SEC Filings

Shareholders—Not PR Operatives and Media Editors—Should Decide Fermi’s Future

DALLAS, June 18, 2026 /PRNewswire/ — Believing that shareholders deserve transparency to determine Fermi’s future, Toby Neugebauer, co-founder and largest shareholder of Fermi Inc. (“Fermi” or the “Company”), responds directly to recent press inquiries and the incumbent board’s SEC filings. Following the release of Toby’s recent open letter, the market responded immediately with significant positive stock momentum—confirming that the investor community recognizes a dual path of tenant acquisition and pursuing a strategic transaction as the path forward that yields highest value, even before a formal vote has been cast. In response to the last 48 hours’ incredible gains and the incumbent Board’s recent falsehoods, Toby released the following statement:

“What a week. It feels like we, as shareholders, are finally coming together around a unified mission to maximize Fermi’s value. The market has spoken clearly with its positive stock reaction to my open letter. We assume success and look forward to Fermi’s best days ahead. On such a positive week, it’s just unfortunate that we must also deal with some trash. We are great at executing big visions, but we simply can’t compete with a former Governor’s nonstop press attacks. Since April, we did not want to feed into the negativity and remained tight-lipped, all in service of protecting critical negotiations with tenants, our lessor, and project financing. We focused on what matters for the future of Fermi: the overwhelming logic of pursuing an immediate dual-track strategic review and my stellar independent nominees who will oversee it. We kept our guns in their holsters, but unfortunately, the Governor’s and the Fermi board’s escalations create unnecessary doubts for Fermi and pose a direct threat to shareholder momentum. We cannot and will not let editors, PR operators, or lawyers determine the basic information that shareholders receive to make an informed decision. We are going to lay out our responses to reporters and the Company’s misleading SEC filings so you can judge the situation for yourself.”

FERMI TEAM – LED BY TOBY – CLOSED RECORD-SETTING TRANSACTIONS WITH CRITICAL COUNTERPARTIES IN A HIGHLY COMPETITIVE ENVIRONMENT

Toby Neugebauer and his leadership team built Fermi from an abstract idea into a multi-billion-dollar publicly traded company in less than a year. The launch of Fermi 2.0 in December 2025 prepared the company for the stringent requirements of ongoing tier-one tenant negotiations and, contrary to Governor Perry and the Board’s storyline, enabled the successful closure of multiple contracts critical to the company’s long-term capitalization.

A partial list of accomplishments in the arena of the most competitive market in the world – the supply chain for AI compute – during his leadership team’s unmatched 15-month tenure includes:

  • Signed a 99-year ground lease with the Texas Tech University System;
  • Secured over 2 GW of total power generation including procuring the most sought after Siemens units in the world;
  • Garnered 800 MW of high-voltage equipment;
  • Secured up to 200 MW power agreement with Xcel and constructed an 86 MW tie-in;
  • Obtained the nation’s second-largest ~6 GW Clean Air Permit, with an additional ~5 GW permit filed with TCEQ;
  • A highly successful IPO;
  • Secured ~$1 billion in financing facilities, the majority from the world’s leading infrastructure lender (MUFG);
  • Negotiated significant tax abatements with local and county districts;
  • Filed a free trade zone application, which required significant local, state, and federal approvals;
  • Assembled one of the top nuclear teams in the world, having successfully built 16 reactors to date, on time and on budget;
  • Submitted the first large-scale nuclear Combined Operating License (COL) application accepted for review by the Nuclear Regulatory Commission (NRC) in over 15 years;
  • The NRC announced Project Matador as an inaugural participant in the environmental impact statement pilot program to expedite nuclear regulatory approvals;
  • Partnered with Hyundai E&C—the only company to have successfully built 24 nuclear reactors globally, ten of them simultaneously, on time and on budget;
  • Hyundai E&C initiated Fermi’s front-end engineering design study and featured Fermi’s nuclear leadership at its large-scale Nuclear Technology Seminar in Dallas to engage contractors and strengthen the U.S. nuclear supply chain and workforce readiness;
  • Ordered key nuclear long-lead-time equipment from Doosan Enerbility;
  • Installed a 450 MMcfpd natural gas pipeline;
  • Secured 2.5 MGD of water from the City of Amarillo;
  • Created a path to ~18.5 MGD of maximum peaking availability via site-adjacent properties, with water line and tower one complete;
  • Received the first six Siemens SGT800s in port in Houston; and
  • Acquired GE 6B Frame turbines, which are currently being refurbished in Houston.

All the while minimizing dilution to shareholders.

By the March 28, 2026 board meeting, the operational progress of Fermi 2.0 was unanimously applauded and celebrated by the Fermi board.

Tenant Negotiations

During his tenure, Neugebauer quickly established that while securing preliminary letters of intent is simple, finalizing multi-billion-dollar project financing facilities in a volatile data center financing environment is where actual execution matters.

  • Navigating Market Pressures: After months of constructive negotiations, conversations with Tenant One stalled over stringent Service Level Agreement penalties and Liquidated Damages provisions that undermined the financeability of the contract. Emboldened by stock price pressure resulting from Steven Meisel shopping a 56 million share block and in light of Oracle’s difficulties in the financing market, Tenant One and Fermi were unable to close all outstanding items. Simply put, Fermi could not accept performance penalties that, if not met, were designed to bankrupt the company, especially given that delays in negotiation had not pushed back delivery timelines.

  • Protecting the Company: Backed by Board director Lee McIntire and General Counsel George Wentz, Mr. Neugebauer and the deal team made the courageous decision to walk away from those out-of-market terms in favor of more stable alternatives.

  • Tenant One Remained Active: Despite the board’s narrative, that initial tenant continued negotiating with Fermi’s deal team, co-led by Anna Bofa, well into January. Toby continues to believe a deal could actually materialize with them to this day.

  • Abrupt Disruption: As noted in the March 30 earnings call, the team was instructed not to announce tentative agreements prematurely. Just days before Toby’s termination without cause, the deal team had made monumental progress toward a definitive agreement with a potential tenant. The entire core deal team departed immediately following his termination.

Enforcing High Accountability Standards

The data center development landscape is currently littered with stalled projects, bloated budgets, and severe contractor cost overruns. Toby refused to let Fermi become another industry statistic. He demanded that Fermi deliver strictly on time and on budget.

As part of Toby’s Fermi 2.0 initiative, underperforming, overengineering, or overbilling partners who had grown accustomed to unchecked time-and-materials arrangements were systematically renegotiated or terminated.

Building a Championship Team – Toby Is Not Easy to Work For

Toby has a track record of building successful teams. As his Chief of Staff Angela Breuers said:

“People join Toby’s team and continue to play for the toughest coach in the league because it gives them the opportunity to accomplish things they never thought possible with an actual shot at a national championship.”

Not a single employee resigned during Mr. Neugebauer’s tenure as CEO; yet nine key executives and senior managers overseeing finance, permitting, community engagement, and tenant acquisition have departed since his termination without cause. Among them was Lexi Swearingen, former Fermi Media Director—and someone who has known and worked with Governor Perry for 15 years—who stated in her resignation letter:

“It is with a very heavy heart that I leave a company that, as a patriot, I know our nation desperately needs. I do not believe the Board’s decision is the correct one for Fermi America, the executive leadership team, employees like me who have given so much to make it successful, our investors, the Amarillo community that has supported us, or our nation. I wish the Board could have been at Semafor this week to see just one example of how well this team, led by Toby, executed. I have worked with and for many talented and amazing people—and I know I will again. But this team you are losing is one of a kind…”

Lexi Swearingen is not a Toby loyalist by default. She is a Perry loyalist by history. That she resigned anyway speaks directly to what this board did and why.

In total, these executives walked away from hundreds of millions of dollars in incentive compensation.

Neugebauer Not Seeking Power, But Providing Solutions

Neugebauer has been consistent—he has no desire to return as CEO of Fermi—a fact he made even clearer by championing John Sellers of Double Eagle to immediately take the helm in this week’s Open Letter. His only desire is for Fermi’s board to fulfill its fiduciary obligations and consider all options on the table, including a full-value strategic transaction, to ensure maximum shareholder value. He has not sold a single share since the IPO—because he knows what it is worth. His interests are fully aligned with those of his fellow shareholders, and he is committed to running a strategic process with an extremely qualified, impartial board that would fairly consider a sale or strategic partnerships to maximize value.

Toby is focused on the 3 C’s: cost of Capital, Construction expertise, and Customer – and has no intention of seeking a transaction for anything less than full value.

MYTH VS. FACT: BALANCING THE RECORD

1. The Lutnick Conversation


False Fermi Claims:
Toby “publicly accosted” Commerce Secretary Howard Lutnick at an industry conference, allegedly blocking Fermi’s capacity to secure billions of dollars of Korean investment as part of the Korean Trade Deal.

The Facts:

  • Toby has known Secretary Lutnick for years. While using words his wife was not pleased with, he spoke to the Secretary as the administration speaks to itself—because that’s the relationship they had and what the business required.
  • Secretary Lutnick was reportedly blocking tens of billions of dollars that Korea wanted to invest to jumpstart American nuclear in Amarillo, Texas, as part of the Korean Trade Deal. Project Matador was at the top of the Korean priority investment list.
  • Senior NVIDIA conference leaders invited Toby to join them for dinner the night after the Lutnick conversation at a VIP reception.
  • The day after the conversation in question, Secretary Lutnick reached out to Mr. Neugebauer through a high-ranking intermediary with commercial terms that Toby refused.
  • After the Lutnick conversation, Cody Campbell and others confirmed to Mr. Neugebauer that Secretary Lutnick had nothing negative to say about him.
  • Newmark, which was acting as Fermi’s intermediary with hyperscalers, confirmed in writing to Neugebauer and verbally to Fermi’s board that the conversation had zero impact on tenant engagement.
  • Fermi had a productive, substantive meeting with the Department of Commerce the week before Mr. Neugebauer’s ouster, as the board was well aware.
  • The federal partnerships Mr. Neugebauer built speak for themselves: the first large-scale nuclear COL application accepted by the NRC in over 15 years, support in the Siemens turbine procurement, and the NRC pilot program.

Why does this matter? The Lutnick interaction is being used as a justification for calling the lease into question—a move that three law firms deemed meritless—as well as for Toby’s termination, which the board has otherwise been unable to defend. The actual record—what happened the day and weeks that followed, the complete lack of interest from any other news outlet, the productive Commerce meeting the week before the firing, and the Company’s remarkable federal partnerships—reflects the opposite of what the filing implies.

2. The Source of the Politico Story


False Fermi Claims:
Neugebauer’s assertion that a negative Politico leak was intentionally planted by an internal board member is entirely unsupported by credible evidence.

The Facts:

  • Mr. Campbell told Toby that he had received a call about the Lutnick story before it ran. Toby knew it was from Governor Perry and gave Mr. Campbell three opportunities to deny it—none were taken. The story was reported by only one political outlet, days after the conversation, and no other outlet followed.
  • Fermi’s political lobbyists—several of whom represented Perry in his presidential race—called and texted Toby, warning that a Politico story was coming while vehemently denying any involvement in the leak, which was perceived as an attempt to cover their tracks.
  • On Saturday, March 28, 2026, during a meeting attended by a room full of senior Fermi leaders, directors Marius Haas and Lee McIntire explicitly stated to Toby and the executive staff that they suspected Rick Perry and his political consultants were the direct source of the Politico leak. Both directors stated their intent to request Mr. Perry’s phone records to formally investigate the matter.

Why does this matter? Fermi’s filing characterizes the Politico-leak allegation as something Mr. Neugebauer raised that the company found unsupported. The contemporaneous record shows the opposite—two of the directors who later voted to fire him told him and a room of witnesses that they themselves believed a fellow board member was likely the source, warranting further investigation. Yet the two people who were with Toby the night of the Lutnick conversation, and those who spoke with him directly afterward, were never interviewed.

3. The “Independent” Investigation


False Fermi Claims:
The Risk & Disclosure Committee utilized independent outside counsel to perform a rigorous review sufficient to back a for-cause termination.

The Facts:

  • In Neugebauer’s entire tenure as CEO, not one concern about his leadership was ever put in writing—not a letter, not an email, not a text. At the March 28 board meeting, weeks before the firing, the board unanimously approved multi-million-dollar compensation awards recognizing the team’s achievements under Toby’s leadership. In the days leading up to his firing, the stock was up 36%.
  • There is not a single board meeting with Mr. Neugebauer present where criticisms of him were raised.
  • The firm engaged by the board never interviewed Toby Neugebauer once—failing to ask him a single question regarding the allegations. They similarly failed to interview the leadership and team members who worked alongside him daily. While all board members agreed on the record to turn over their devices for data verification, to our knowledge, only Toby and former CFO Miles Everson actually complied.
  • Fermi’s senior executives wrote formal letters to the board in explicit, full support of Toby, no letter more glowing than the one from Jacobo Ortiz. None of the senior management communications referenced any of the personal or operational rumors being circulated today, because the team knew the conflict was entirely political.
  • Furthermore, the departing management team members left hundreds of millions of dollars of unvested incentive compensation on the table. Sophisticated executives do not walk away from life-changing compensation packages for a leader who “blew up deals.”

Why does this matter? First, the Board filed with the SEC that Toby departed the company, misleading investors. Then, Toby corrected the Board saying he was fired without cause. Only when the Board realized they had to terminate Toby from the Board for-cause in order to take his board seat, did they falsely conjure grounds for such a removal. A for-cause termination supported by an investigation that never interviewed the person being investigated, never interviewed the team most familiar with him, and rests on conduct that no director ever raised in writing during his entire tenure is not an investigation. It is a post-hoc justification pushed by a small portion of the board, led by Rick Perry.

4. “Lack of Transparency” and Communication Breakdowns


False Fermi Claims:
Toby was terminated due to a failure to communicate transparently and repeated unauthorized public disclosures.

The Facts:

  • Toby always maintained an open line to everyone, hosting collaborative morning alignment calls with the entire leadership team and maintaining on-site visibility at the Amarillo project facilities.
  • He provided the board with multiple lengthy, detailed written memos beginning in January 2026 outlining clear management concerns regarding the Meisel overhang, Perry, Campbell, and internal governance issues—none of which received formal written responses.
  • He has never been presented with any evidence of unauthorized public disclosures.
  • He invited board members to team meetings and encouraged their attendance in meetings with counterparties.

Why does this matter? Neugebauer publicly calls on Fermi to release—or give him permission to release—all communications between him and any or all board members, including minutes of board meetings he attended, that contradict the above. The board will not, because the contemporaneous written record does not support the story the board is now telling. The “no paper trail” is the story.

5. The Coordinated Stock Dump


False Fermi Claims:
Share price decline was Neugebauer’s fault.

The Facts:

  • In April 2025, Steven Meisel received roughly 56 million shares of Fermi stock from Griffin Perry via Pencross Energy.
  • To show his utter disrespect for what Fermi had built, Steven Meisel threatened to blow up the entire IPO after pricing over the lockup. Toby refused to give in because he had a written agreement with Griffin that Steven’s shares were non-voting, which was affirmed by the underwriter and company counsel at the time.
  • In October and November 2025, multiple tier-one investment banks warned Fermi leadership that Pencross was aggressively shopping that massive 56 million share block against a minor 35 million share public IPO float. Meisel openly phoned Fermi’s internal accounting department to boast that his shares were completely free of lock-up constraints.
  • The Company’s largest creditor, Macquarie, which led the Series C round, sought to terminate its relationship over the issue at Christmas, saying Meisel and Perry were ‘taking the stock to zero.’ They were dumbfounded that the only person not locked up was Griffin Perry’s office mate.
  • Public filings confirm that Pencross’s beneficial ownership dropped from 56.25 million shares to 28.4 million shares by March 31, 2026—meaning roughly 28 million shares were systematically dumped into the open market while the stock collapsed, severely undermining Fermi’s leverage with prospective hyperscale tenants.
  • Simultaneously, co-founder Griffin Perry personally sold 11 million founder shares on the open market in March 2026 for approximately $56.3 million—an action no committed co-founder would take. Two weeks later, his father, Rick Perry—whom Griffin placed on the Fermi board through his company Caddis’ nomination—led the effort to terminate Toby.
  • The number one person calling on the Company to sue Governor Perry and Griffin Perry in Q1 2026, in his capacity as a shareholder, was Fermi’s own General Counsel, George Wentz, while Chief Operating Officer Jacobo Ortiz proposed to investors in Puerto Rico that they do the same. Neugebauer encouraged both men to delay taking action until the tenant deal was completed. 
  • One of the toughest decisions of his career, Toby owned the December decision that led to the CIAC announcement.

Why does this matter? Toby acknowledges his decision to walk away from Tenant One contributed to the stock decline. However, far more consequential was that Fermi’s filing dismisses the Pencross overhang as an “inherent feature in an IPO of 6% of the Company’s total capital” while blaming Toby for the stock decline. That characterization is not credible against the documented record: a 56 million share block against a 35 million share float, marketed by banks who flagged it, sold roughly in half on the open market in six months, with 25% short interest at IPO when no one else could sell. That is not an inherent feature. That is a coordinated dump.

6. The Comparison Fermi Invites: Who Actually Sold


False Fermi Claims:
Mr. Neugebauer’s statement that he has “not sold a single share since the IPO” is “materially misleading,” because “concurrently with the IPO” he sold 4,082,858 shares through Vicksburg Investments Management LLC, and the REIT 5/50 explanation was “a convenient excuse to sell shares.”

The Facts:

  • The transaction in question was executed in August 2025, before the IPO—not “concurrently with” it—at the request of Fermi’s underwriters, at a substantial discount to the IPO price.
  • The purpose was to bring the Neugebauer family’s combined ownership stake below 40%, at the underwriters’ demand, to support a successful IPO.
  • Mr. Neugebauer sold only what was required. Post-IPO, he publicly recommended the best REIT 5/50 solution for the top shareholders should be addressed through charitable giving. Since the IPO, Mr. Neugebauer has not sold a single share. Not one. Now compare that record to the conduct Fermi’s filing intentionally ignores:
  • Between them, the Perrys and Mr. Meisel have dumped roughly 40 million shares onto the open market since the IPO. That is the overhang that crushed the stock and weakened Fermi’s hand in tenant negotiations.

Why does this matter? Fermi’s filing invites the comparison. The comparison is overwhelming. Mr. Neugebauer sold the minimum his own underwriters demanded, at a discount, before the IPO, to make the offering possible, and has held every share since. The Perrys and Mr. Meisel have dumped roughly 40 million shares on the open market after the IPO, crushing the value of every other shareholder’s holding. Fermi’s attempt to equate those records is not an argument. It is an admission they have nothing better.

7. The GloriFi Historical Narrative


False Fermi Claims:
Past venture restructuring indicates an operational pattern that justifies the board’s recent corporate interventions.

The Facts:

  • Miles Everson’s company was the largest creditor of GloriFi’s primary subsidiary and threw the entity into involuntary bankruptcy, yet he turned around three years later wanting to be the CFO of Toby’s next major company, Fermi.
  • Throughout that bankruptcy process, 100% of the secured creditors and three major law firms who were unsecured creditors completely supported Toby Neugebauer.
  • The bankruptcy judge in the GloriFi case found no pre-petition bad behavior by Mr. Neugebauer while he was running the company.
  • As publicly reported, Locke Lord fully investigated the claims regarding GloriFi—including thorough interviews with more than 20 people and a review of thousands of documents—and cleared his name. In addition, Haynes Boone (on behalf of the Company) and Vinson & Elkins (on behalf of UBS and Cantor Fitzgerald) reviewed all of these matters as part of clearing Fermi for the IPO. Both firms cleared the S-1 with full disclosures.
  • Whether as investors, board members, consultants, or full-time employees, Rick and Griffin Perry, Marius Haas, Anna Bofa, Jacobo Ortiz, Miles Everson, Cathy Landtroop, Charlie Hamilton, and Rodrigo Acuna were all involved and fully aware of what happened at GloriFi—and eagerly followed Toby to Fermi.
  • Allegations about alcohol abuse while leading Fermi are false. Lexi Swearingen, former Fermi Media Director: “These are false claims hurled by people with an agenda who have no idea about the facts.” In addition, both of Toby’s chiefs of staff at GloriFi and Fermi – two highly educated Georgetown and Penn graduates of high accomplishment who sat in on 80 percent of his meetings – affirmed that these allegations were false. The same allegations were fully investigated at GloriFi and found to be false, resulting in the judge allowing Toby’s defamation claims to move forward.

Why does this matter? Attempting to relitigate any of these past matters in the press, three years on and after multiple independent reviews, is what an entrenched board does when it cannot defend its own conduct. 100% of the secured creditors and three major law firms that knew the most about GloriFi supported Mr. Neugebauer. The same lawyers who took GloriFi down now represent Meisel and Campbell.

CONCLUSION: THE DEFINITIVE PATTERN

When analyzed chronologically, the evidence reveals an unmistakable corporate pattern: an entrenched board faction determined to remove a founder, constructed a post-hoc justification without basic due process, ignored their own compliance parameters, and utilized spin to obscure substantial insider stock liquidations.

While the positive market response to our recent communications shows that shareholders recognize the true engine of Fermi’s value, the critical next step is ensuring each shareholder’s voice is legally counted. Toby strongly urges all shareholders to protect their equity, disregard the board’s WHITE revocation cards, and sign the GREEN agent designation card to ensure the first true shareholder vote in Fermi’s history goes forward.

IMPORTANT INFORMATION

Toby Neugebauer and his affiliated entities, Vicksburg Investments Management LLC and Melissa A. Neugebauer 2020 Trust (collectively with Mr. Neugebauer, the “Fermi Founder Parties”), David A. Daglio, Charles M. Elson, John T. Jimenez, Janet Yang, Sheila Hooda, and Juan A. Pujadas (collectively, the “Participants”) have filed a definitive proxy statement on Schedule 14A, accompanying GREEN agent designation card, and other relevant documents with the SEC in connection with the solicitation of agent designations for calling a special meeting of shareholders to be held as promptly as practicable (the “Special Meeting”).

THE PARTICIPANTS STRONGLY ADVISE ALL SHAREHOLDERS OF THE COMPANY TO READ THE DEFINITIVE PROXY STATEMENT AND OTHER PROXY MATERIALS, INCLUDING THE GREEN AGENT DESIGNATIONS CARD, THAT HAVE BEEN AND WILL BE FILED BY THE PARTICIPANTS AS THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION. SUCH PROXY MATERIALS ARE AND WILL BE AVAILABLE AT NO CHARGE ON THE SEC’S WEB SITE AT HTTP://WWW.SEC.GOV. IN ADDITION, THE PARTICIPANTS WILL PROVIDE COPIES OF THE PROXY STATEMENT WITHOUT CHARGE, WHEN AVAILABLE, UPON REQUEST.

Mr. Neugebauer beneficially owns 146,516,035 shares of the Company’s common stock, $0.001 par value per share (the “Common Stock”), composed of: (i) Vicksburg Investments Management LLC beneficially owns 44,656,376 shares of Common Stock; (ii) 94,359,659 shares of Common Stock beneficially owned by the Melissa A. Neugebauer 2020 Trust; and (iii) 7,500,000 shares of Common Stock underlying restricted stock units held by Mr. Neugebauer that vested in connection with his termination without cause. As of the date hereof, none of the other Participants beneficially own any shares of Common Stock.

 

Cision View original content:https://www.prnewswire.com/news-releases/the-market-has-spoken-wants-neugebauer-and-fermi-board-to-maximize-shareholder-value-and-enhance-management-302805068.html

SOURCE Toby Neugebauer

Jabil Expands Manufacturing Capacity in India

Jabil Expands Manufacturing Capacity in India

Factory expansion reinforces company’s commitment to India, coinciding with recent Memorandum of Understanding (MoU) signing with Maharashtra government

PUNE, India–(BUSINESS WIRE)–Jabil Inc. (NYSE: JBL), a global leader in engineering, supply chain, and manufacturing solutions, today announced the opening of a new factory in Pune, marking a significant expansion of the company’s India manufacturing capacity.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618400989/en/

Jabil's new facility in Pune, India, was inaugurated on 16 June 2026, with honored guests including (left to right) Shri Dilip Walse Patil, Executive Vice President and Chief Operations Officer Andrew Priestley, The Honourable Chief Minister of Maharashtra, Shri Devendra Fadnavis Ji, Honorable Minister for Railways, Information & Broadcasting, and Electronics & Information Technology, Shri Ashwini Vaishnaw Ji, and Shri Dnyaneshwar Katke.

Jabil’s new facility in Pune, India, was inaugurated on 16 June 2026, with honored guests including (left to right) Shri Dilip Walse Patil, Executive Vice President and Chief Operations Officer Andrew Priestley, The Honourable Chief Minister of Maharashtra, Shri Devendra Fadnavis Ji, Honorable Minister for Railways, Information & Broadcasting, and Electronics & Information Technology, Shri Ashwini Vaishnaw Ji, and Shri Dnyaneshwar Katke.

Located in the Maharashtra Industrial Development Corporation (MIDC) industrial zone, this facility is the latest addition to Jabil’s India footprint, which has grown from 500,000 square feet to 1.2 million square feet over the past year. This ongoing growth has also increased Jabil’s regional headcount from 5,000 to almost 11,000 employees.

“Expanding in Pune reflects Jabil’s long-term commitment to India, especially as the country grows its position as a global manufacturing leader,” said Andy Priestley, Jabil’s Executive Vice President of Operations. “This new facility will help us bring together more skilled manufacturing talent and engineering capability to build the highest quality products with speed at scale. As we continue developing our people here in Pune, we’re strengthening Jabil’s ability to execute consistently in India.”

The expansion reflects Jabil’s confidence in Maharashtra as a strategic location for advanced manufacturing and comes on the heels of a MoU signing with the state government.

“Maharashtra continues to be a preferred destination for global manufacturers because of our skilled workforce, and commitment to enabling investment and growth,” said Devendra Fadnavis, Chief Minister of Maharashtra. “Jabil’s expansion in Pune is a welcome addition to the state’s manufacturing landscape and an encouraging example of how world-class companies are contributing to India’s industrial progress, job creation, and long-term economic development.”

“As the Make in India initiative continues to evolve, we remain committed to building a robust ecosystem that enables companies like Jabil to innovate, scale, and thrive in India,” said Ashwini Vaishnaw, Minister of Railways, Information and Broadcasting, and Electronics and Information Technology.

In India, Jabil serves a wide range of industries, such as telecommunications, AI cloud data centres, automotive, and digital commerce.

In 2025, Jabil was recognized with the Great Place To Work Certification in India; selected as one of India’s top 100 mid-sized companies to work for; and named as India’s Best Workplaces™ in Electronics 2025.

To learn about and apply for open positions at Jabil’s new Pune facility, visit jabil.com/careers.

About Jabil

At Jabil (NYSE: JBL), we are proud to be a trusted partner for the world’s top brands, offering comprehensive engineering, supply chain, and manufacturing solutions. With 60 years of experience across industries and a vast network of over 100 sites worldwide, Jabil combines global reach with local expertise to deliver both scalable and customized solutions. Our commitment extends beyond business success as we strive to build sustainable processes that minimize environmental impact and foster vibrant and diverse communities around the globe. Discover more at www.jabil.com.

Investor Contact

Adam Berry

Senior Vice President, Investor Relations and Corporate Affairs

[email protected]

Media Contact

Aileen Han

Director, Enterprise Marketing and Communications

[email protected]

KEYWORDS: India Asia Pacific

INDUSTRY KEYWORDS:

MEDIA:

Photo
Photo
Jabil’s new facility in Pune, India, was inaugurated on 16 June 2026, with honored guests including (left to right) Shri Dilip Walse Patil, Executive Vice President and Chief Operations Officer Andrew Priestley, The Honourable Chief Minister of Maharashtra, Shri Devendra Fadnavis Ji, Honorable Minister for Railways, Information & Broadcasting, and Electronics & Information Technology, Shri Ashwini Vaishnaw Ji, and Shri Dnyaneshwar Katke.
Logo
Logo

INNSUITES FY 2027 Q1 RECORDS CONSOLIDATED NET INCOME PROFIT; REVERSE MERGER EXPLORATION CONTINUES

Phoenix, AZ, June 18, 2026 (GLOBE NEWSWIRE) — InnSuites Hospitality Trust (NYSE American: IHT) achieved Fiscal First Quarter Consolidated Net Income profitability of $74,702, which is a modest improvement of $35,672, over the prior year Fiscal First Quarter. IHT reported record Hotel Revenue results of approximately $2.2 million in the Fiscal First Quarter of 2027 (February 1, 2026, to April 30, 2026).

Consolidated Net Income before non-cash items of depreciation and non-cash Best Western Travel Rewards credit expenses was $307,326 for the 2027 First Fiscal Quarter ended April 30, 2026 (February 1, 2026, through April 30, 2026).

Combined Hotel Occupancy jumped to 85.37%, while the Revenue Per Available Room and Suites (REVPAR), modestly increased to $88.23.

IHT hotel operations were strong in the 2026 Fiscal Year ended January 31, 2026, and are contributing to a solid start in the current 2027 Fiscal Year. Combined Hotel May Revenue for both hotels was $652,786, which led to total Hotel Revenue of approximately $2.9 million for the First Four Fiscal Months of Fiscal 2027, a new combined record level. IHT’s strong hotel operating results are reflected in three of the five most recent Fiscal Years profitable, even after accounting for substantial non-cash depreciation expense. These are positive signs for InnSuites, as progress remains strong, despite early 2026 Travel Industry uncertainty.

InnSuites Hospitality Trust continues to explore diversification opportunities and opportunities to increase Equity, potentially including a reverse merger, which is of high interest.

RRF LLLP, the 76% owned subsidiary Management Company for IHT, manages the IHT Hotels, and InnDependent Boutique Collection (IBC Hotels, LLC). IBC is a diversification opportunity for IHT.

In the process of ownership and management of branded and unbranded hotels, IHT recognized an unfulfilled need to provide hotel reservations, branding, and hotel services for global independent hotels, which at the time and still represent half the hotels in the world. In February 2014, IHT founded IBC Hotels, LLC to exploit this unfulfilled opportunity, developing reservations, branding, and related hotel services doing business as “InnDependent Boutique Collection “(IBC Hotels). Initial success in providing reservations for an IHT operated independent hotel was substantial. As this independent hotel services opportunity and the size of this potential demand was increasingly recognized in the travel industry, IBC Hotels was sold in August 2018 to a foreign hotel company planning expansion of independent hotel reservations and services internationally. IBC growth slowed in 2020 with the Covid Travel shutdown.

On March 5, 2025, REF , an investment entity owned by the chairman and family of IHT majority IHT shareholder, purchased IBC Hotels, LLC, and hired RRF LLLP, the management company subsidiary of InnSuites Hospitality Trust (IHT), to manage the rebirth of IBC, to benefit from the substantial unfulfilled need worldwide for independent hotel and resort reservations, Boutique branding, and related hotel services. In the process, RRF LLLP, obtained a five-year option to purchase, at cost, IBC Hotels, LLC. This option is believed to provide IHT a valuable upside opportunity, if successful, to profit from the revitalization of InnDependent Boutique Collection (IBC Hotels).

With the continued growing demand for electricity from data centers plus the influx of electric vehicles, as well as projected growing needs for artificial intelligence, increased demand for electricity over the next five years is projected to approximately double, which bodes well for the IHT investment in UniGen Power, Inc. This product is a potentially power industry disruptive relatively clean energy cost effective electric generation innovation, and even though it is high risk, it offers IHT substantial high upside potential.

On February 20, 2026, James Wirth was elected Chairman, CEO, and President of UniGen, while Marc Berg was elected as Vice Chairman, EVP, and Secretary/Treasurer of UniGen, with plans to rejuvenate the UniGen progress to benefit all the UniGen debt and equity holders, including IHT. Target date for the first two prototype engines to be ready for testing is in less than two years.

IHT management believes that due to real estate held on the books of IHT at book values significantly below current market value, due to clean energy diversification high profit potential ahead, IBC independent hotel services prospects, a potential reverse merger possibility, and improving hospitality profitability before non-cash depreciation and other non-cash items, the IHT future looks bright.

Our most recent dividend at the start of the current Fiscal Year 2027 extended IHT’s uninterrupted, continuous annual dividends to 56 years, since 1971, when IHT was first listed on the NYSE.

For more information, visit www.innsuitestrust.com and www.innsuites.com.

Forward-Looking Statements

With the exception of historical information, matters discussed in this news release may include “forward-looking statements” within the meaning of the federal securities laws. All statements regarding IHT’s review and exploration of a potential reverse merger, strategic, operational, and structural alternative diversification investments, increasing equity, and expected associated costs and benefits are forward-looking. Actual developments and business decisions may differ materially from those expressed or implied by such forward-looking statements. Important factors, among others, that could cause IHT’s actual results and future actions to differ materially from those described in forward-looking statements include economic effects of international conflicts as well as tariffs, the uncertain outcome, impact, effects and results of IHT’s success in finding qualified purchasers for its hospitality real estate, or a reverse merger partner, the success of additional financing increasing equity, and timing of the UniGen clean energy and other potential diversification innovations, the continuation of annual dividends in the year(s) ahead, collections of receivables, and other risks discussed in IHT’s SEC filings. IHT expressly disclaims any obligation to update any forward-looking statement contained in this news release to reflect events or circumstances that may arise after the date hereof, all of which are expressly qualified by the foregoing, other than as required by applicable law.

FOR FURTHER INFORMATION:

Marc Berg, Executive Vice President
602-944-1500
email: [email protected]

INNSUITES HOSPITALITY CENTRE
1730 E. NORTHERN AVENUE, #122
Phoenix, Arizona 85020
Phone: 602-944-1500



Accenture Investigation Initiated: SueWallSt Investigates the Officers and Directors of Accenture (ACN)

PR Newswire

Accenture guided investors to expect 3-5% full-year revenue growth while undisclosed headwinds were already pressuring the business — then cut the outlook and watched the stock fall more than 18%

NEW YORK, June 18, 2026 /PRNewswire/ — Accenture (NYSE: ACN) shareholders lost approximately 18.5% of their investment value today after the company slashed its fiscal year 2026 revenue growth forecast to 3-4%, down from the 3-5% range it had previously provided. Those who lost money on ACN shares are encouraged to submit their information immediately. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (888) SueWallSt.

SueWallSt.com

Accenture’s prior guidance, issued during its fiscal Q2 earnings report on March 19, 2026, projected 3-5% revenue growth for full-year fiscal 2026, uplifted from Q1’s previous 2-5% target. Today’s Q3 results narrowed that range by cutting the upper bound, and the stock recorded its largest single-day percentage decline on record. The Q3 revenue figure of $18.7 billion came in below analyst expectations of $18.78 billion.

Morgan Stanley had downgraded Accenture to Hold on June 16 and cut its price target from $240 to $177, citing concerns that anticipated AI spending rationalization had “not played out.” Two days later, the company’s own guidance revision confirmed that the growth trajectory management had projected just three months earlier was no longer achievable.

Shareholders who purchased ACN and suffered losses may click here to discuss their legal rights. You may also reach Joseph E. Levi, Esq. at [email protected] or (888) SueWallSt.

ABOUT THE FIRM — For over two decades, SueWallSt has represented shareholders in securities investigations and actions. Ranked in ISS Top 50 for seven consecutive years.

Frequently Asked Questions About the ACN Investigation

Q: Who is conducting the ACN investigation?A: SueWallSt is investigating potential securities law concerns on behalf of investors who purchased ACN securities and suffered financial losses. The firm is nationally recognized, ranked in the ISS Top 50 for seven consecutive years, and has recovered hundreds of millions of dollars for aggrieved investors.

Q: Which statements are being investigated as potentially misleading?A: The investigation concerns whether Accenture made materially false or misleading statements regarding its full-year fiscal 2026 revenue growth outlook. When the company revised its guidance downward on June 18, 2026, the stock price declined sharply.

Q: What do ACN investors need to do right now?A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact SueWallSt for a free, no-obligation evaluation at [email protected] or (888) SueWallSt. No immediate action is required to remain eligible to participate in the investigation.

Q: What if I already sold my ACN shares — can I still recover losses?A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought ACN and sold at a loss may still participate in the investigation.

Q: What does it cost me to participate?A: Nothing. Securities investigations are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.

Q: Do I need to go to court or give testimony?A: No. Participating in the investigation does not require court appearances or depositions.

Q: What if I live outside the United States?A: U.S. securities investigations generally cover purchases on U.S. exchanges regardless of the investor’s country of residence.

CONTACT:\
SueWallSt\
Joseph E. Levi, Esq.\
Ed Korsinsky, Esq.\
33 Whitehall Street, 27th Floor\
New York, NY 10004\
[email protected]\
Tel: (888) SueWallSt\
Fax: (212) 363-7171

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/accenture-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-accenture-acn-302804925.html

SOURCE SueWallSt.com

Novocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR)

PR Newswire

Novocure reported its Phase 3 TRIDENT Trial failed to achieve its primary endpoint of an increase in overall survival for patients at the start of chemoradiation. Shares were down more than 18% midday on June 18, 2026.

NEW YORK,, June 18, 2026 /PRNewswire/ — Investors who held Novocure Limited (NASDAQ: NVCR) shares lost more than $3 per share on June 18, 2026, when the stock had fallen over 18% in a single session. Shareholders who suffered a loss are encouraged to submit their information now . You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (888) SueWallSt.

SueWallSt.com

On its Q3 2025 earnings call, then-CEO Ashley Cordova indicated TRIDENT was examining “the benefit of starting Tumor Treating Fields concurrently with chemo radiation in newly diagnosed GBM,” as opposed to the current practice of waiting until after the “chemo radiation cycle ends.” On January 14, 2026, during Novocure’s presentation at a healthcare conference, CEO Frank Leonard indicated they expected, for the majority of patients in the study, that “we’ll produce better duration of therapy overall than in our prior study.” He further claimed, with respect to the upcoming readouts, that the company had put itself “in a place to build additional evidence over the coming years to keep this growth going.”

Several months later, on June 18, 2026, shares were falling more than 18% midday after the Company disclosed that its Phase 3 TRIDENT trial missed the primary overall survival endpoint, wiping out roughly $3.30 per share in value.

Shareholders who lost money on their NVCR investment are encouraged to click here to discuss their legal rights . You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (888) SueWallSt.

SueWallSt — Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered.

Frequently Asked Questions About the NVCR Investigation

Q: Who is eligible to participate in the NVCR investigation? A: Investors who purchased NVCR stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses — not on whether you still hold the shares.

Q: How much did NVCR stock drop? A: Shares had collapsed more than 18%, a decline of rover $3 per share, after the Company disclosed that its Phase 3 TRIDENT glioblastoma trial missed the primary overall survival endpoint. Investors who purchased shares at elevated prices may be entitled to compensation.

Q: What do NVCR investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact SueWallSt for a free, no-obligation evaluation at [email protected] or (888) SueWallSt. No immediate action is required to remain eligible to participate in the investigation.

Q: What happens after I contact SueWallSt? A: An attorney will review your trading history at no cost and provide an initial assessment of your potential recovery.

Q: What if I already sold my NVCR shares — can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought NVCR and sold at a loss may still participate in the investigation.

Q: What does it cost me to participate? A: Nothing. Securities investigations are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.

CONTACT:
SueWallSt
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (888) SueWallSt
Fax: (212) 363-7171

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/novocure-limited-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-novocure-limited-nvcr-302804902.html

SOURCE SueWallSt.com

Align Technology Announces Board Leadership Transition. C. Raymond Larkin, Jr. to Retire as Chairman and Kevin Conroy to be Appointed Chairman Effective July 1, 2026

Align Technology Announces Board Leadership Transition. C. Raymond Larkin, Jr. to Retire as Chairman and Kevin Conroy to be Appointed Chairman Effective July 1, 2026

TEMPE, Ariz.–(BUSINESS WIRE)–
Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that C. Raymond Larkin, Jr. will retireas Chairman of the Board effective July 1, 2026, following more than 20 years of distinguished service on Align’s Board of Directors. Mr. Larkin will continue to serve on the Board and as a member of the Nominating and Governance Committee through December 31, 2026, to support a smooth transition.

Kevin Conroy will succeed Mr. Larkin as Chairman of the Board, effective July 1, 2026. Mr. Conroy has served as an independent director since his appointment to the Board in December 2023 and Chair of the Compensation and Human Capital Committee of the Board since January 2026.

“On behalf of the entire Board and management team, I would like to express our deep gratitude to Ray for his extraordinary leadership, partnership, and enduring contributions to Align over more than two decades,” said Joe Hogan, Align Technology president and chief executive officer. “Ray has been instrumental in guiding Align through multiple phases of growth, innovation, and scale. His strategic insight, deep experience in healthcare, and unwavering commitment to strong governance have helped shape Align into the global leader it is today.”

Mr. Hogan continued, “We are pleased to welcome Kevin as our next Chairman. Kevin brings extensive experience as a board leader and recently as CEO of Exact Sciences prior to its acquisition by Abbott Laboratories in March 2026. He has demonstrated a strong track record of creating stockholder value, and deep expertise in healthcare, technology, and strategy. His leadership will help guide Align through our next chapter of growth and innovation.”

Mr. Larkin added, “It has been an honor to serve as Chairman of Align. I am incredibly proud of all that Align has achieved and confident in its continued leadership in digital dentistry. I look forward to supporting Kevin and the Board during this transition and seeing Align continue to transform smiles and improve patient outcomes around the world well into the future.”

Mr. Conroy said, “I am honored to be appointed Chairman of Align’s Board. Align has a strong foundation, an exceptional leadership team, and significant opportunities ahead. I look forward to working closely with Joe, the Board, and management to continue driving innovation, expanding access to digital orthodontics, and creating long-term value for our stockholders.”

ABOUT C. RAYMOND LARKIN, JR.

Mr. Larkin has served as a member of Align’s Board since 2004. He has decades of leadership experience in the medical device and healthcare industries, including serving as President and Chief Executive Officer of Nellcor Puritan Bennett, where he led the company’s growth to nearly $1 billion in revenue and helped establish pulse oximetry as a global standard of care. Throughout his tenure at Align, Mr. Larkin has provided strategic guidance across periods of significant growth and innovation, drawing on his extensive public and private company board experience and deep expertise in healthcare.

ABOUT KEVIN CONROY

Mr. Conroy has served as an independent director of Align since December 2023 and Chair of the Compensation and Human Capital Committee of the Board since January 2026. He brings extensive experience as a business, legal, and strategic leader, including serving as Chairman and Chief Executive Officer of Exact Sciences Corp. until its acquisition by Abbott Laboratories in March 2026, where he led the commercialization of Cologuard and grew the company to $3.25 billion in annual revenue while serving millions of patients. Prior to Exact Sciences, Mr. Conroy served as President and CEO of Third Wave Technologies and held leadership roles at GE Healthcare. He currently serves on the board of Abbott Laboratories and brings deep expertise in healthcare innovation, strategy, and governance.

About Align Technology, Inc.

Align Technology designs and manufactures the Invisalign® System, the most advanced clear aligner system in the world, iTero™ intraoral scanners and services, and exocad™ CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for approximately 299.5 thousand doctor customers and are key to accessing Align’s 600 million consumer market opportunity worldwide. Over the past 29 years, Align has helped doctors treat approximately 22.8 million patients with the Invisalign System and is driving the evolution in digital dentistry through the Align™ Digital Platform, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit www.aligntech.com for more information.

For additional information about the Invisalign system or to find an Invisalign doctor in your area, please visit www.invisalign.com. For additional information about the iTero digital scanning system, please visit www.itero.com. For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit www.exocad.com.

Invisalign, iTero, exocad, Align, Align Digital Platform and iTero Lumina are trademarks of Align Technology, Inc.

Align Technology

Madelyn Valente

(909) 833-5839

[email protected]

Zeno Group

Sarah Karlson

(828) 551-4201

[email protected]

KEYWORDS: Arizona United States North America

INDUSTRY KEYWORDS: Health Medical Devices Technology Other Health Software Dental General Health

MEDIA:

Logo
Logo

Agibank Concludes Its Seventh Issuance of Public Financial Bills in Brazil

Agibank Concludes Its Seventh Issuance of Public Financial Bills in Brazil

The BRL 500 million transaction closed on June 18

SÃO PAULO–(BUSINESS WIRE)–
Agibank, a bank that operates a hybrid platform combining the efficiency and scalability of digital with the proximity and service of a physical presence, announces the closing of the issuance of its seventh Public Financial Bill (Letra Financeira Pública). Agibank is a subsidiary of Agi Inc. (NYSE: AGBK) (“Agi”).

With an aggregate principal amount of BRL 500 million and a maximum tenor of 36 months, the proceeds will be used to fund the bank’s lending operations. The issuance was structured in two tranches, with rates of CDI +0.60% and CDI +0.75%, and tenors of 24 and 36 months, respectively.

“We are pleased with this issuance, completing another market transaction with pricing efficiency and further reinforcing our position as a recurring debt issuer in the Brazilian market. Transactions like this provide us with greater visibility and create the necessary foundation to scale in a market where we have deep expertise: secured lending for Brazilian consumers,” said Marcello Dubeux, Chief Financial Officer and Investor Relations Officer at Agi.

About Agi

Agi stands for a banking experience that welcomes and empowers all Brazilians through a business model that is unique in Brazil. Designed to serve a customer base that represents the majority of the Brazilian population, our model addresses needs that remain outside the priorities of traditional large banks and purely digital banks. We fill a gap in the market by serving, with quality and dignity, customers who are often overlooked.

Our hybrid model combines the best of both worlds: a fully digital bank that is light, fast, and easy to use, complemented by physical branches that offer a welcoming, agile, and accessible in-person experience for all Brazilians. We develop tailored solutions and provide a simple, inclusive customer journey for non-digital-native clients, creating a meaningful competitive advantage. This approach enables us to attract more customers, build long-lasting relationships, and strengthen our growth trajectory.

No Offer

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as “expect,” “anticipate,” “should,” “believe,” “hope,” “target,” “project,” “goals,” “estimate,” “potential,” “predict,” “may,” “will,” “might,” “could,” “intend,” variations of these terms or the negative of these terms and similar expressions are intended to identify these statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond Agi Inc’s control. Agi Inc’s actual results could differ materially from those stated or implied in forward-looking statements due to several factors, including but not limited to: competition, regulatory or tax developments, changes in its business, industry, or local or global economic and other developments

Press Contact

Email: [email protected]

Website: investors.agiinc.com

KEYWORDS: Latin America South America Brazil

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA: